Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Antineoplastic Agents
/ therapeutic use
Bortezomib
/ therapeutic use
Female
Hematopoietic Stem Cell Transplantation
/ methods
Humans
Immunologic Factors
/ therapeutic use
Lenalidomide
/ therapeutic use
Maintenance Chemotherapy
/ methods
Male
Middle Aged
Multiple Myeloma
/ therapy
Retrospective Studies
Transplantation, Autologous
/ methods
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
07 01 2021
07 01 2021
Historique:
received:
16
07
2020
accepted:
10
11
2020
revised:
29
10
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m
Identifiants
pubmed: 33414374
doi: 10.1038/s41408-020-00390-3
pii: 10.1038/s41408-020-00390-3
pmc: PMC7791127
doi:
Substances chimiques
Antineoplastic Agents
0
Immunologic Factors
0
Bortezomib
69G8BD63PP
Lenalidomide
F0P408N6V4
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1Références
Haematologica. 2015 Jul;100(7):964-9
pubmed: 25840597
Leukemia. 2018 Feb;32(2):383-390
pubmed: 28761118
Lancet Haematol. 2020 Jun;7(6):e456-e468
pubmed: 32359506
N Engl J Med. 2012 May 10;366(19):1782-91
pubmed: 22571202
N Engl J Med. 2014 Sep 4;371(10):906-17
pubmed: 25184863
Blood. 2012 Jan 26;119(4):940-8
pubmed: 22160383
Haematologica. 2014 Jan;99(1):148-54
pubmed: 23996482
Lancet Oncol. 2011 May;12(5):431-40
pubmed: 21507715
J Clin Oncol. 2017 Oct 10;35(29):3279-3289
pubmed: 28742454
Expert Rev Hematol. 2019 Feb;12(2):107-118
pubmed: 30696304
N Engl J Med. 2012 May 10;366(19):1770-81
pubmed: 22571201
Lancet. 2019 Jan 19;393(10168):253-264
pubmed: 30545780
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
Leukemia. 2019 Jan;33(1):258-261
pubmed: 29959413
Leukemia. 2015 Aug;29(8):1721-9
pubmed: 25787915
Leukemia. 2018 Mar;32(3):712-718
pubmed: 28848227
J Natl Compr Canc Netw. 2017 Feb;15(2):230-269
pubmed: 28188192
J Clin Oncol. 2007 Jun 10;25(17):2434-41
pubmed: 17485707
J Clin Oncol. 2019 Mar 1;37(7):589-597
pubmed: 30653422
Br J Haematol. 2016 Jun;173(5):731-41
pubmed: 26990892
Leukemia. 2020 Jul;34(7):1853-1865
pubmed: 32034285
Mayo Clin Proc. 2013 Apr;88(4):360-76
pubmed: 23541011
Lancet Oncol. 2019 Jan;20(1):57-73
pubmed: 30559051
N Engl J Med. 2014 Sep 4;371(10):895-905
pubmed: 25184862
Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61
pubmed: 28453614
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
N Engl J Med. 2003 Dec 25;349(26):2495-502
pubmed: 14695409
Blood. 2016 May 26;127(21):2569-74
pubmed: 27002117
Bone Marrow Transplant. 2018 Jun;53(6):701-707
pubmed: 29703965
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
J Clin Oncol. 2012 Aug 20;30(24):2946-55
pubmed: 22802322